SG10201706265PA - Novel compounds and compositions for targeting cancer stem cells - Google Patents

Novel compounds and compositions for targeting cancer stem cells

Info

Publication number
SG10201706265PA
SG10201706265PA SG10201706265PA SG10201706265PA SG10201706265PA SG 10201706265P A SG10201706265P A SG 10201706265PA SG 10201706265P A SG10201706265P A SG 10201706265PA SG 10201706265P A SG10201706265P A SG 10201706265PA SG 10201706265P A SG10201706265P A SG 10201706265PA
Authority
SG
Singapore
Prior art keywords
compositions
stem cells
novel compounds
cancer stem
targeting cancer
Prior art date
Application number
SG10201706265PA
Other languages
English (en)
Inventor
David Leggett
Chiang Jia Li
Youzhi Li
Wei Li
Original Assignee
Boston Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical Inc filed Critical Boston Biomedical Inc
Publication of SG10201706265PA publication Critical patent/SG10201706265PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92Naphthofurans; Hydrogenated naphthofurans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
SG10201706265PA 2010-03-19 2011-03-21 Novel compounds and compositions for targeting cancer stem cells SG10201706265PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31588610P 2010-03-19 2010-03-19
US31589010P 2010-03-19 2010-03-19
US32581410P 2010-04-19 2010-04-19

Publications (1)

Publication Number Publication Date
SG10201706265PA true SG10201706265PA (en) 2017-08-30

Family

ID=50940329

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201502079VA SG10201502079VA (en) 2010-03-19 2011-03-21 Novel compounds and compositions for targeting cancer stem cells
SG10201706265PA SG10201706265PA (en) 2010-03-19 2011-03-21 Novel compounds and compositions for targeting cancer stem cells
SG10201704745UA SG10201704745UA (en) 2010-03-19 2011-03-21 Novel compounds and compositions for targeting cancer stem cells

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201502079VA SG10201502079VA (en) 2010-03-19 2011-03-21 Novel compounds and compositions for targeting cancer stem cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201704745UA SG10201704745UA (en) 2010-03-19 2011-03-21 Novel compounds and compositions for targeting cancer stem cells

Country Status (11)

Country Link
EP (2) EP3295796A1 (enExample)
JP (11) JP2014098050A (enExample)
CN (3) CN107311969B (enExample)
CA (3) CA2959951A1 (enExample)
DK (1) DK3108750T3 (enExample)
ES (1) ES2689928T3 (enExample)
HU (1) HUE066482T2 (enExample)
NZ (2) NZ701237A (enExample)
PT (1) PT2547205T (enExample)
RU (2) RU2657750C1 (enExample)
SG (3) SG10201502079VA (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5688840B2 (ja) 2007-09-10 2015-03-25 ボストン バイオメディカル, インコーポレイテッド 新規のStat3経路阻害剤及び癌幹細胞阻害剤
SG10201502079VA (en) * 2010-03-19 2015-06-29 Boston Biomedical Inc Novel compounds and compositions for targeting cancer stem cells
LT2547205T (lt) * 2010-03-19 2024-06-10 1Globe Biomedical Co., Ltd. Nauji tikslinio poveikio vėžio kamieninėms ląstelėms būdai
MX2015014181A (es) 2013-04-09 2016-05-24 Boston Biomedical Inc 2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer.
US20180140572A1 (en) * 2015-06-03 2018-05-24 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
GB201515387D0 (en) * 2015-08-28 2015-10-14 Amazentis Sa Compositions
GB201515391D0 (en) * 2015-08-28 2015-10-14 Amazentis Sa Compositions
JP6751658B2 (ja) 2016-11-15 2020-09-09 クラリオン株式会社 音声認識装置、音声認識システム
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61205257A (ja) * 1985-03-08 1986-09-11 Ishihara Sangyo Kaisha Ltd ベンゾイルウレア系化合物、その製法及びそれを含有する抗ガン剤
EP0945131A1 (de) * 1998-03-27 1999-09-29 Boehringer Ingelheim Pharma KG Perorale Wirkstoff-Suspension
WO2000044774A2 (en) * 1999-01-27 2000-08-03 The University Of South Florida Inhibition of stat3 signal transduction for human cancer therapy
WO2004026253A2 (en) * 2002-09-17 2004-04-01 Arqule, Inc. Novel lapacho compounds and methods of use thereof
AR042052A1 (es) * 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
JP5288791B2 (ja) * 2005-01-28 2013-09-11 武田薬品工業株式会社 難水溶性物質含有微細化組成物
JP2006290871A (ja) * 2005-03-16 2006-10-26 Taheebo Japan Kk 抗癌性を示す化合物およびその中間体ならびにそれらの製造方法
TW200803854A (en) * 2005-09-30 2008-01-16 Smithkline Beecham Corp Pharmaceutical compositions
EP1860126A1 (en) * 2006-05-26 2007-11-28 INEOS Manufacturing Belgium NV Polyolefin powder
JP5688840B2 (ja) * 2007-09-10 2015-03-25 ボストン バイオメディカル, インコーポレイテッド 新規のStat3経路阻害剤及び癌幹細胞阻害剤
US8822482B2 (en) * 2008-07-08 2014-09-02 Beta Pharma, Inc. Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof
SG10201502079VA (en) * 2010-03-19 2015-06-29 Boston Biomedical Inc Novel compounds and compositions for targeting cancer stem cells
WO2011116398A1 (en) * 2010-03-19 2011-09-22 Boston Biomedical, Inc. Novel compounds and compositions for targeting cancer stem cells
LT2547205T (lt) * 2010-03-19 2024-06-10 1Globe Biomedical Co., Ltd. Nauji tikslinio poveikio vėžio kamieninėms ląstelėms būdai

Also Published As

Publication number Publication date
JP2016222723A (ja) 2016-12-28
JP2020063308A (ja) 2020-04-23
JP2022020002A (ja) 2022-01-27
CA2959951A1 (en) 2011-09-22
JP2018115209A (ja) 2018-07-26
JP2015232037A (ja) 2015-12-24
JP2014098048A (ja) 2014-05-29
JP2015098489A (ja) 2015-05-28
JP2020114888A (ja) 2020-07-30
EP3108750B1 (en) 2018-07-04
SG10201502079VA (en) 2015-06-29
CN104016951A (zh) 2014-09-03
PT2547205T (pt) 2024-05-27
EP3108750A1 (en) 2016-12-28
JP2018002744A (ja) 2018-01-11
HUE066482T2 (hu) 2024-08-28
RU2015142279A (ru) 2018-12-28
CA2959931A1 (en) 2011-09-22
CN107311969B (zh) 2022-01-28
DK3108750T3 (en) 2018-10-22
CN107311969A (zh) 2017-11-03
CA2993363A1 (en) 2011-09-22
CN104016951B (zh) 2016-07-13
RU2657750C1 (ru) 2018-06-15
JP6246169B2 (ja) 2017-12-13
JP2014098049A (ja) 2014-05-29
SG10201704745UA (en) 2017-07-28
JP2014098050A (ja) 2014-05-29
JP5993390B2 (ja) 2016-09-14
CN106860443A (zh) 2017-06-20
NZ701237A (en) 2016-04-29
EP3295796A1 (en) 2018-03-21
RU2015142279A3 (enExample) 2019-02-26
ES2689928T3 (es) 2018-11-16
NZ712826A (en) 2017-03-31

Similar Documents

Publication Publication Date Title
LT2547205T (lt) Nauji tikslinio poveikio vėžio kamieninėms ląstelėms būdai
PL2640893T3 (pl) Kompozycje
GB201002983D0 (en) Nutritinal composition
GB201009549D0 (en) Compositions
GB201006200D0 (en) Composition
SG10201704745UA (en) Novel compounds and compositions for targeting cancer stem cells
GB201021186D0 (en) Composition
GB201019297D0 (en) Improved compositions
GB201009546D0 (en) Compositions
GB201010954D0 (en) Compositions
EP2625231A4 (en) INK PRESERVATIVE COMPOSITIONS
GB201002861D0 (en) Compositions
WO2011116344A9 (en) Targeting cancer stem cells
PL2534242T3 (pl) Polepszona kompozycja do hamowania proliferacji komórek nowotworowych
GB201017048D0 (en) Composition
IL214545A0 (en) Compositions and methods for visualizing and eliminating cancer stem cells
GB201016970D0 (en) Composition
IL225952A0 (en) preparations@rokkhot
GB201014591D0 (en) Compositions
GB201007790D0 (en) Compositions
GB201005927D0 (en) Improved composition
GB201004717D0 (en) Composition
EP2575743A4 (en) WELD-INHIBITING COMPOSITIONS
PL2545016T3 (pl) Kompozycja zawierająca fosforan hemipotasowy
GB201019606D0 (en) Compositions